Brooks Laboratories (BOM:533543) EBIT: ₹254.2 Mil (TTM As of Mar. 2026)


BOM:533543 Brooks Laboratories Ltd BOM:533543
67 GF Score
Price ₹77.71
GF Value ₹117.81
Valuation Significantly Undervalued
! 3 Warning Signs
View Full Analysis

What is Brooks Laboratories EBIT?

Brooks Laboratories BOM:533543 +2.25% 67 EBIT is ₹254.2 Mil as of Mar. 2026. GuruFocus rates BOM:533543 with a GF Score™ of 67/100 and a GF Value™ of ₹117.81 (Significantly Undervalued). The stock has 3 warning signs investors should review.

Brooks Laboratories's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2026 was ₹16.1 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2026 was ₹254.2 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Brooks Laboratories's annualized ROC % for the quarter that ended in Mar. 2026 was 0.82%. Brooks Laboratories's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 21.59%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Brooks Laboratories's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 11.07%.

Brooks Laboratories  (BOM:533543) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Brooks Laboratories's annualized ROC % for the quarter that ended in Mar. 2026 is calculated as:

ROC % (Q: Mar. 2026 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2025 ) + Invested Capital (Q: Mar. 2026 ))/ count )
=10.608 * ( 1 - 0% )/( (0 + 1288.838)/ 1 )
=10.608/1288.838
=0.82 %

where

Invested Capital(Q: Dec. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=0 - 0 - ( 0 - max(0, 0 - 0+0))
=0

Invested Capital(Q: Mar. 2026 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=1481.739 - 114.37 - ( 78.531 - max(0, 218.142 - 374.153+78.531))
=1288.838

Note: The Operating Income data used here is four times the quarterly (Mar. 2026) data.

2. Joel Greenblatt's definition of Return on Capital:

Brooks Laboratories's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 is calculated as:

ROC (Joel Greenblatt) %(Q: Mar. 2026 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2025  Q: Mar. 2026
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=64.488/( ( (0 + max(0, 0)) + (157.094 + max(141.643, 0)) )/ 1 )
=64.488/( ( 0 + 298.737 )/ 1 )
=64.488/298.737
=21.59 %

where Working Capital is:

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 0) - (0 + 0 + 0)
=0

Working Capital(Q: Mar. 2026 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(161.148 + 110.219 + 24.255) - (114.37 + 0 + 39.609)
=141.643

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Brooks Laboratories's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Mar. 2026 )
=254.188/2295.763
=11.07 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Brooks Laboratories EBIT Related Terms

Brooks Laboratories EBIT Historical Data

* Premium members only.

The historical data trend for Brooks Laboratories's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Brooks Laboratories EBIT Chart

Brooks Laboratories Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only -210.66 -364.16 -188.41 -87.63 254.19

Brooks Laboratories Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -10.22 98.86 82.60 56.60 16.12

BOM:533543 vs ZTS, UTHR: EBIT Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Brooks Laboratories's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Brooks Laboratories EV-to-EBIT vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Brooks Laboratories's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Brooks Laboratories's EV-to-EBIT falls into.


BOM:533543
67GF Score
Brooks Laboratories Ltd BOM:533543
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Brooks Laboratories EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹254.2 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of ₹254.2 Mil mean?
Brooks Laboratories (BOM:533543) has a EBIT of ₹254.2 Mil as of Mar. 2026. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Brooks Laboratories.
Is Brooks Laboratories' EBIT too high?
Brooks Laboratories' current EBIT is ₹254.2 Mil. Overall, Brooks Laboratories has a GF Score™ of 67/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Brooks Laboratories' EBIT compare to ZTS and UTHR?
Brooks Laboratories' EBIT of ₹254.2 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Drug Manufacturers company?
A good EBIT depends on the Drug Manufacturers industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Brooks Laboratories. Brooks Laboratories's current EBIT is ₹254.2 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Brooks Laboratories stock overvalued right now?
Based on GuruFocus' analysis, Brooks Laboratories (BOM:533543) is currently considered Significantly Undervalued. The stock's GF Value™ is ₹117.81, compared to a current price of ₹77.71 — trading 34% below its estimated fair value. The current EBIT is ₹254.2 Mil. Brooks Laboratories' overall GF Score™ is 67/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Brooks Laboratories (BOM:533543), the current EBIT is ₹254.2 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Brooks Laboratories (BOM:533543) Overvalued in 2026?

Based on GuruFocus' analysis, Brooks Laboratories stock appears to be undervalued. The current stock price of ₹77.71 is trading 34% below its estimated GF Value™ of ₹117.81. GuruFocus considers Brooks Laboratories to be Significantly Undervalued.

Key valuation signals for BOM:533543:

  • EBIT: ₹254.2 Mil
  • GF Value™: ₹117.81 vs. price of ₹77.71 (34% below fair value)
  • GF Score™: 67/100 with 3 warning signs

No single metric tells the full story. See the BOM:533543 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Brooks Laboratories Business Description

Other Exchanges BROOKS:India
Address Near Andheri Kurla Road, 201, The Summit Business Park, Behind Guru Nanak Petrol Pump, Andheri (East), Mumbai, MH, IND, 400 093
Brooks Laboratories Ltd is a pharmaceutical manufacturer focused on developing and producing a broad range of generic medicines. Its key segments include injectables, tablets, and dry syrups, with product lines covering antibiotics such as beta-lactams and cephalosporins as well as general critical care injectables. The company operates manufacturing facilities compliant with international quality standards located in India, serving both domestic and international markets. Revenue is generated through contract manufacturing and sales of pharmaceutical formulations distributed broadly across regulated and semi-regulated international markets. The company has obtained regulatory certifications from multiple countries to comply with international standards for pharmaceutical manufacturing.
67GF Score

Get the complete analysis for BOM:533543

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹77.71
Price
₹117.81
GF Value